Actelion hits six-year high after favorable FDA approval for drug

ZURICH (Reuters) - Shares in Swiss group Actelion climbed more than five percent to their highest since late 2007 on Monday on optimism it has a viable product to secure sales and profit after U.S. approval for a new heart and lung drug with a favorable label. (Source: Reuters: Health)

Source: http://www.medworm.com/index.php?rid=7692540&cid=u_0_26_f&fid=23271&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2Freuters%2FhealthNews%2F%7E3%2FI88wIgla5ns%2Fstory01.htm

phlebotomy classes in alabama phlebotomy certification new york phlebotomy certification houston